Nasdaq
$0.6170▲ 0.08%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $181.8MShares out 2.900M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 9.29Pre-market26.09.29 20:268-KKey event#●●●#●●●
Invivyd, Inc.Bullish
Invivyd announced positive topline results from its Phase 3 LIBERTY study, demonstrating that its COVID-19 antibody candidate VYD2311 has superior safety and tolerability compared to mRNA-based COVID-19 vaccines. The company plans to submit a Biologics License Application (BLA) to the U.S. FDA for Accelerated Approval, supported by these findings and data from the ongoing DECLARATION study.…more
$0.6170+0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.2After-hours26.09.03 05:404Ownership
Invivyd, Inc.
Insider Ian Sheffield of Invivyd, Inc. filed a report regarding changes in beneficial ownership of securities as of August 31, 2026. This filing serves as a standard disclosure of changes in executive stock holdings.…more
$0.6170+0.08%vs prev closeView filingShare - 9.2After-hours26.09.03 05:403Ownership
Invivyd, Inc.
Invivyd, Inc. has granted a limited power of attorney to designated representatives to execute and file Forms 3, 4, 5, and Form 144 on behalf of its officers and directors in compliance with the Securities Exchange Act. This filing formalizes the delegation of administrative authority for SEC reporting requirements.…more
$0.6170+0.08%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 20:01#●●●#●●●
Invivyd Presents Preclinical Data for Measles Candidate VMS063
Invivyd presented preclinical data for its monoclonal antibody candidate VMS063, which is being developed for the treatment and prevention of measles. As the program is in the early stages, it requires further clinical development and regulatory validation before potential commercialization.…more
$0.6170+0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14Pre-market26.10.14 20:01
●●●●●●●● ●●●●● ●●●●●●
Invivyd has launched a Phase 2 clinical trial for its monoclonal antibody candidate, VYD2311, targeting Long COVID and post-vaccination syndrome. Initial data is expected by mid-2027, and the trial remains in the early stages of development.…more
$0.6170+0.08%vs prev close - 10.5Pre-market26.10.05 20:01
●●●●●●●● ●●●●● ●●●●●●
Invivyd has granted stock options for a total of 157,500 shares to six newly hired non-executive employees. This move is intended as an employment inducement, though it introduces potential share dilution.…more
$0.6170+0.08%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report